Management of Graves Disease With Co-Existing Duffy-Null Phenotype

Area of Science:

• Endocrinology
• Hematology
• Genetics

Background:

• Antithyroid drugs (ATD) are a primary treatment for Graves' disease.
• Neutropenia is a potential side effect of ATD, necessitating baseline monitoring.
• The Duffy-null blood group phenotype is associated with lower baseline absolute neutrophil counts (ANC).

Observation:

• A 37-year-old male with Graves' disease presented with leukopenia and neutropenia.
• The patient was diagnosed with the Duffy-null phenotype.
• Previous neutrophil counts varied, but were consistently lower than standard reference ranges.

Findings:

• The Duffy-null phenotype is characterized by a lower ANC but does not increase infection risk.
• The patient tolerated a standard dose of methimazole (an ATD) without adverse effects.
• Baseline neutropenia in Duffy-null individuals does not contraindicate ATD use.

Implications:

• ATD should not be withheld in patients with the Duffy-null phenotype solely due to their baseline neutropenia.
• Understanding red blood cell phenotypes can inform clinical decisions regarding medication initiation.
• Further research may clarify the specific mechanisms and clinical management of neutropenia in diverse populations.